Update on recruitment of new members for pCODR Expert Review Committee

As previously announced, the CADTH pan-Canadian Oncology Drug Review (pCODR) program is recruiting new members for the pCODR Expert Review ...

Read more →

Health economics update and call for feedback on costing document

CADTH has undertaken an update of the Guidance Document for the Costing Process. This document is intended to help researchers determine ...

Read more →

NICE consults on draft guidance recommending treatments for types of arthritis that affect the spine

NICE has today published draft guidance on adalimumab (Humira, AbbVie), etanercept (Enbrel, Pfizer), infliximab (Remicade, Merck Sharp & Dohme; Inflectra, ...

Read more →

Aprecia Pharmaceuticals receives FDA acceptance for filing for first product using advanced ZipDose technology

Aprecia Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s New Drug ...

Read more →

Cancer patient in $16k hit to stay alive

A NSW leukaemia patient has told of his family's distress trying to raise $16,000 every three weeks for each dose ...

Read more →

Call for feedback: anti-VEGF drugs for retinal conditions

CADTH is pleased to invite all interested parties to provide feedback on the list of included studies being considered for ...

Read more →

AbbVie files New Drug Submission to Health Canada for its investigational, all-oral, interferon-free therapy for the treatment of hepatitis C

AbbVie filed a New Drug Submission (NDS) to Health Canada seeking approval for the company's investigational, all-oral, interferon-free regimen for the ...

Read more →

Melanoma treatment among 50 new medicines added to PBS list

Fifty new and amended medicines have been added to the Pharmaceutical Benefits Scheme. Health Minister Peter Dutton says it means ...
Read more →

Promoting competition key to improving patients’ access to high cost medicines

[:content [\8 \space \A \p \r \i \l \space \2 \0 \1 \4 \space \- \space \P \H \A \R \M \A \C \space \h \a \s \space \a \n \n \o \u \n \c \e \d \space \i \t \s \space \i \n \t \e \n \t \i \o \n \space \t \o \space \t \e \s \t \space \o \u \t \space \a \space \c \o \n \t \e \s \t \a \b \l \e \space \f \u \n \d \space \f \o \r \space \h \i \g \h \space \c \o \s \t \space \m \e \d \i \c \i \n \e \s \space \f \o \r " ..."]]
Read more →

The Yukon to fund treatment with Aubagio for relapsing-remitting multiple sclerosis

Genzyme, a sanofi company, announced today that the Yukon Pharmaceutical Programs have included Aubagio (teriflunomide) 14 mg on the territorial drug ...

Read more →

David Cameron’s flagship Cancer Drugs Fund ‘is a waste of NHS cash’

A furious political row is set to erupt this week over a key part of David Cameron’s health service strategy. ...

Read more →

Summary of the agenda for the PBAC July 2014 meeting

[:content [\1 \space \M \a \y \space \2 \0 \1 \4 \space \- \T \h \e \space \P \B \A \C \space \w \i \l \l \space \c \o \n \s \i \d \e \r \space \5 \0 \space \s \u \b \m \i \s \s \i \o \n \s \space \( \2 \7 \space \m \a \j \o \r \space \& \space \2 \3 \space \m \i \n \o \r \) \space \a \t \space \i \t \s \n \e \x \t \space \s \c \h \e \d \u \l \e \d \space \m \e \e \t \i \n \g \space \i \n \space \J \u \l \y \. \  " ..."]]
Read more →

AbbVie receives Health Canada approval of Holkira Pak for the treatment of chronic genotype 1 hepatitis C

AbbVie receives Health Canada approval for Holkira Pak (ombitasvir/paritaprevir/ritonavir film-coated tablets; dasabuvir film-coated tablets), an all-oral, short-course (12 weeks for the ...

Read more →

SMC - forthcoming submissions

Below a list of forthcoming submissions that have recently been added to the SMC's programme. Information in relation to the drug ...

Read more →

Québec government covers Lemtrada (alemtuzumab) for MS patients

Genzyme, a Sanofi company, announced today that Québec's Institut national d'excellence en santé et services sociaux (INESSS) has recommended that Lemtrada (alemtuzumab) 12 ...

Read more →